This hypothesis combines focused ultrasound (FUS) microbubble-mediated blood-brain barrier disruption with AAV-PHP.eB viral delivery to achieve enhanced microglial-specific IGFBPL1 expression. The approach leverages FUS-induced acoustic cavitation to create transient 10-100 nm paracellular gaps in BBB endothelial tight junctions, dramatically increasing permeability for subsequent AAV-PHP.eB vector passage. Following BBB disruption, systemically administered AAV-PHP.eB particles exploit their enhanced neurotropic properties and AAVR/GPR108/VPS29 receptor interactions for efficient brain penetration. The CX3CR1 promoter system then drives selective IGFBPL1 expression specifically in microglia through binding of myeloid-specific transcription factors PU.1, IRF8, and RUNX1. Once expressed, IGFBPL1 modulates microglial function through multiple pathways: regulating IGF-1/IGF-2 bioavailability and downstream IGF-1R/PI3K/Akt signaling that controls microglial activation states, and engaging αvβ3/α5β1 integrins via RGD motifs to influence microglial adhesion and migration.

This hypothesis combines focused ultrasound (FUS) microbubble-mediated blood-brain barrier disruption with AAV-PHP.eB viral delivery to achieve enhanced microglial-specific IGFBPL1 expression. The approach leverages FUS-induced acoustic cavitation to create transient 10-100 nm paracellular gaps in BBB endothelial tight junctions, dramatically increasing permeability for subsequent AAV-PHP.eB vector passage. Following BBB disruption, systemically administered AAV-PHP.eB particles exploit their enhanced neurotropic properties and AAVR/GPR108/VPS29 receptor interactions for efficient brain penetration. The CX3CR1 promoter system then drives selective IGFBPL1 expression specifically in microglia through binding of myeloid-specific transcription factors PU.1, IRF8, and RUNX1. Once expressed, IGFBPL1 modulates microglial function through multiple pathways: regulating IGF-1/IGF-2 bioavailability and downstream IGF-1R/PI3K/Akt signaling that controls microglial activation states, and engaging αvβ3/α5β1 integrins via RGD motifs to influence microglial adhesion and migration. The temporal coordination is critical—FUS treatment creates a therapeutic window of enhanced BBB permeability lasting 2-6 hours, during which AAV-PHP.eB vectors achieve 10-100 fold increased brain uptake compared to intact BBB conditions. This synergistic approach addresses the primary limitation of viral gene therapy (poor BBB penetration) while maintaining cell-type specificity and avoiding systemic IGFBPL1 expression that could disrupt peripheral IGF signaling.